Efficacy of agomelatine given orally on the quality of remission in elderly depressed patients, after a 12-week treatment period. A randomised, double-blind, flexible-dose international multicentre study with parallel groups versus SSRI drug. Twelve-week treatment plus optional continuation for 12 weeks.

Submission date	Recruitment status  No longer recruiting	Prospectively registered	
24/01/2006		☐ Protocol	
Registration date	Overall study status	Statistical analysis plan	
31/03/2006	Completed	[X] Results	
<b>Last Edited</b> 18/04/2018	Condition category  Mental and Behavioural Disorders	Individual participant data	

## Plain English summary of protocol

Not provided at time of registration and not expected to be available in the future

# Contact information

# Type(s)

Scientific

#### Contact name

Dr Thierry Bougerol

## Contact details

CHU de Grenoble-Hopital Sud Psychiatrie de l'Adulte BP 185 Cedex 09 Grenoble France 38042

# Additional identifiers

## Clinical Trials Information System (CTIS)

2005-002388-95

## Protocol serial number

CL3-20098-048

# Study information

#### Scientific Title

Efficacy of agomelatine (25 to 50 mg/day) given orally on quality of remission in elderly depressed patients, after a 12-week treatment period. A randomised, double-blind, flexible-dose international multicentre study with parallel groups versus paroxetine (20 to 30 mg/day). Twelve-week treatment plus optional continuation for 12 weeks.

## **Study objectives**

To show the efficacy of agomelatine in improving the quality of remission in elderly depressed patients.

On 26/11/2012 the anticipated end date of this trial was updated from 30/10/2007 to 30/04/2008.

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

First approved by the Ethical Committee of Clinical Investigations, Clinical Hospital of San Carlos (Comite Etico de Investigacion Clinica, Hospital Clinico, San Carlos) on 05/08/2005 in Spain, reference number: 05/165-R

## Study design

Randomised double-blind flexible-dose international multicentre study with parallel groups versus SSRI drug

## Primary study design

Interventional

## Study type(s)

**Treatment** 

## Health condition(s) or problem(s) studied

Major depressive disorder

#### **Interventions**

Agomelatine versus SSRI drug

#### **Intervention Type**

Drug

## **Phase**

Not Applicable

## Drug/device/biological/vaccine name(s)

Agomelatine

## Primary outcome(s)

Quality of sleep

## Key secondary outcome(s))

- 1. Other sleep patterns
- 2. Quality of life
- 3. Daytime drowsiness
- 4. Residual symptoms of depression

## Completion date

30/04/2008

# **Eligibility**

## Key inclusion criteria

Out-patients aged at least 60 years with recurrent major depressive episode according to diagnostic and statistical manual of mental disorders (DSM) IV

## Participant type(s)

Patient

## Healthy volunteers allowed

No

## Age group

Adult

#### Sex

All

## Key exclusion criteria

- 1. Patients treated with electroconvulsive therapy (ECT) within the last three months
- 2. Insight-oriented and structured psychotherapy started within the three months before inclusion
- 3. Light-therapy started within two weeks before inclusion
- 4. Current diagnosis of neurological disorders
- 5. Cognitive dysfunction
- 6. Severe or uncontrolled organic disease, likely to interfere with the conduct of the study

## Date of first enrolment

07/10/2005

#### Date of final enrolment

30/04/2008

# Locations

# Austria Belgium Denmark France Hungary Italy Norway Poland Portugal Spain

Countries of recruitment

Study participating centre CHU de Grenoble-Hopital Sud Grenoble France 38042

# Sponsor information

# Organisation

Institut de Recherches Internationales Servier (France)

## **ROR**

https://ror.org/034e7c066

# Funder(s)

# Funder type

Industry

## Funder Name

Institut de Recherches Internationales Servier (France)

# **Results and Publications**

## Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study will be available upon request from https://clinicaltrials.servier.com if a Marketing Authorisation has been granted after 1st January 2014.

# IPD sharing plan summary

Available on request

## **Study outputs**

Output type	Details	Date created Date added	Peer reviewed?	Patient-facing?
Results article	results	01/01/2013	Yes	No
Basic results			No	No
Participant information sheet	Participant information sheet	11/11/2025 11/11/2025	No	Yes